RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 111 filers reported holding RHYTHM PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $650,474 | +39.5% | 28,374 | +0.3% | 0.00% | – |
| Q2 2023 | $466,271 | -95.2% | 28,276 | -91.5% | 0.00% | -100.0% |
| Q4 2022 | $9,734,030 | +5023.2% | 334,273 | +1925.0% | 0.00% | – |
| Q1 2022 | $190,000 | -21.8% | 16,507 | -31.9% | 0.00% | – |
| Q4 2021 | $243,000 | -31.9% | 24,248 | -11.3% | 0.00% | – |
| Q3 2021 | $357,000 | -27.9% | 27,333 | +8.0% | 0.00% | – |
| Q2 2021 | $495,000 | +35.2% | 25,308 | +47.1% | 0.00% | – |
| Q1 2021 | $366,000 | -15.7% | 17,207 | +17.8% | 0.00% | – |
| Q4 2020 | $434,000 | +100.9% | 14,612 | +46.6% | 0.00% | – |
| Q3 2020 | $216,000 | -4.4% | 9,964 | -1.7% | 0.00% | – |
| Q2 2020 | $226,000 | +33.7% | 10,134 | -8.9% | 0.00% | – |
| Q1 2020 | $169,000 | – | 11,127 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |